:Genetics

The investigators in the institute of cancer of OR had identified a new gene that caused cancer. The research land-breaking appears monday in the Oncogeneperiodical of cancer of the nature.

The gene and its protein, both called RBM3, are vital for the division of stack in normal stacks. In cancers, the low levels of the oxygen in tumors make with that the amount of this protein goes above dramtica. This makes with that the stacks of cancer divide uncontrollably, leading to the increased formation of the tumor.

The investigators had used the new powerful technology “to silence” the protein and to reduce genetically the level of RBM3 in stacks cancerous. The approach stopped cancer of the growth and lead it it the death of the stack. The new technique was successfully tested in diverse types of cancers - chest, pancreas, colon, lung, ovarian and prostate.

“we are excited on this discovery because the majority of cancers is thought to come of mutations in the genes, and our studies, for the first time, we had shown that too much of this type of protein he makes with really that the normal stacks turn in stacks of cancer,” Shrikant cancer of in the project had said Anant of cancer in the institute of main investigator OR and a biologist, Ph.D..

Anant said that they had found protein RBM3 in each period of training of many cancers, and the amount of increased protein as cancer grew. The protein helped cancer to grow more quickly, prevents the death of the stack and was party to suit that gave to form the new boats of blood to feed the tumor.

“this process, called angiogenesis, is essential for the growth of the tumor and suggests perhaps that this to whiten RBM3 can be an extremely powerful tool of continuous meeting to many and to all tumors,” said Anant.

One room to finance for the research of cancer comes of a concession $800,000 of the national justinian codes of the health with the deep remains of the university of the college of Oklahoma of the medicine. The following stage for Anant, Dr. Courtney Houchen and its team of research in the center of sciences of the health of OR is to develop the agents who obstruct the function of the protein in a variety of cancers. The investigators wait to start clinical experimentations in OR approximately five years.

The article was adaptou today for Medical Notice of the release of the original press.

Source: ClayDiane
University of Oklahoma